Institute Of Hematology & Blood Diseases Hospital, China
Clinical trials sponsored by Institute Of Hematology & Blood Diseases Hospital, China, explained in plain language.
-
New combo therapy targets tough lymphoma cases
Disease control OngoingThis study tests a new treatment for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment combines two advanced immune therapies: a bispecific antibody and CAR-T cells. The goal is to see if t…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 01, 2026 16:00 UTC
-
New antibody therapy targets tough AL amyloidosis cases
Disease control TerminatedThis study was designed to test a drug called CM-336 in people with AL amyloidosis whose disease came back or didn't get better enough after initial treatment. The drug works by helping the immune system attack harmful cells. The trial was withdrawn before enrolling any participa…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
500 hemophilia patients in china to reveal hidden costs and care gaps
Knowledge-focused OngoingThis study tracks 500 male patients aged 12 and older with severe hemophilia A or B in China. Researchers will collect data on treatment costs, access to care, and how the disease affects daily life. The goal is to identify gaps in care and help improve treatment for people with …
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated May 01, 2026 16:01 UTC